Monitoring Strategies for Managing ADC Toxicities in mBC

Author(s):

Heather Moore, BCOP, CPP, PharmD, Jodi Taraba, PharmD, MS, BCOP

Panelists discuss how pharmacists should monitor neutropenia, diarrhea, and mucositis from sacituzumab govitecan (SG); interstitial lung disease (ILD) and neutropenia from trastuzumab deruxtecan (T-DXd); and neutropenia and ILD from datopotamab deruxtecan (Dato-DXd). Proactive management is essential for patient safety.

EP: 1.Navigating HER2 Heterogeneity: Precision Pathways in Breast Cancer Treatment

EP: 2.Metastatic Breast Cancer Treatment Guidelines and the Nuances of HER2-Low Disease in Clinical Practice

EP: 3.Transforming Breast Cancer Treatment Through ADC-Targeting Mechanisms

EP: 4.How ADC Design Influences Efficacy and Safety

EP: 5.Beyond HER2: Expanding the Biomarker Testing Landscape in Metastatic Breast Cancer

EP: 6.Comparing Approved ADC Options in HER2-Negative and HER2-Low Breast Cancer

EP: 7.Key Considerations for Oncology Pharmacists When Selecting and Sequencing ADC Therapies

EP: 8.Emerging ADC Clinical Trial Evidence in Breast Cancer Treatment

EP: 9.Personalizing ADC Therapy in mBC Based on Patient Characteristics and Prior Therapies

EP: 10.Practical Insights for Pharmacists on ADC Administration, Patient Experience, and Supportive Care

EP: 11.Managing ADC Toxicities and Infusion Reactions With Supportive Care Strategies

Now Viewing

EP: 12.Monitoring Strategies for Managing ADC Toxicities in mBC

EP: 13.Optimizing ADC Supportive Care Prescribing and AE Management With Institutional Workflows

EP: 14.Discussing ADC Risks, Benefits, and Regimens With Patients

EP: 15.Interdisciplinary Approaches to Breast Cancer Care and ADC Treatment Barriers Due to Social Determinants of Health

EP: 16.Concluding Remarks: Collaborative Expertise in an Era of Emerging Cancer Therapies

Video content above has been prompted by the following:

Toxicity management is critical for patients on antibody-drug conjugates (ADCs). What are the most important ADC-related AEs that pharmacists should monitor (eg, neutropenia, diarrhea, ILD, mucositis) for T-DXd, SG, and Dato-DXd?